J. Naidoo Et Al. , "Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial," LUNG CANCER , vol.166, pp.84-93, 2022
Naidoo, J. Et Al. 2022. Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial. LUNG CANCER , vol.166 , 84-93.
Naidoo, J., Vansteenkiste, J. F., Faivre-Finn, C., ÖZGÜROĞLU, M., Murakami, S., Hui, R., ... Quantin, X.(2022). Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial. LUNG CANCER , vol.166, 84-93.
Naidoo, Jarushka Et Al. "Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial," LUNG CANCER , vol.166, 84-93, 2022
Naidoo, Jarushka Et Al. "Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial." LUNG CANCER , vol.166, pp.84-93, 2022
Naidoo, J. Et Al. (2022) . "Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial." LUNG CANCER , vol.166, pp.84-93.
@article{article, author={Jarushka Naidoo Et Al. }, title={Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial}, journal={LUNG CANCER}, year=2022, pages={84-93} }